Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

London man Dan Godley survived stage three pancreatic cancer with support from his fiancée, a dachshund puppy and groundbreaking treatment. He ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...

Programme testing for BRCA mutation to resume next year after successful launch results, Health Secretary tells JC ...

Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medic ...

Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology ...

The annual San Antonio Breast Cancer Symposium was held from Dec. 9 to 12 in San Antonio. Attendees included medical ...

Bec Pickering, from Melbourne, has just one wish for her two young daughters after a devastating diagnosis turned her own ...

A natural vitamin A transporter, RBP4, can awaken latent HIV through NF-κB signalling, offering a new angle for cure ...

With Strand Life Sciences, Reliance is pushing genetic testing toward the mainstream. Incumbents, regulators and doctors are ...

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...

Introduction: Prostate cancer (PCa) is the second most common type of cancer among the male population. Men carrying mutations in the BRCA1 and BRCA2 genes are known to have a greater risk of ...